Aun cuando no puede descartarse una participacin directa de SEMA, la influencia de la reduccin adiposa y la mejora de la disfuncin adipocitaria contribuyen probablemente al perfil evolutivo de los factores de riesgo cardiovascular
Diabetes Obes Metab 22(12):24872492 Verma S, Bhatta M, Davies M, Deanfield JE, Garvey WT, Jensen C, et al (2023) Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
Figure 3E)
Here are some key aspects of GLP-1 agonists: Target appetite reduction Mimic natural GLP-1 Support sustained weight loss Benefit metabolic health Reduce cardiovascular risks These drugs are part of a growing trend to incorporate medication into weight management strategies
It enhances muscle protein synthesis rates and reduces protein breakdown
Greco, and M